Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pox Virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Pox Virus. Displaying page 1 of 1.
    EudraCT Number: 2010-018334-51 Sponsor Protocol Number: POX-MVA-032 Start Date*: 2010-07-15
    Sponsor Name:Bavarian Nordic A/S
    Full Title: An open-label, non-controlled study to immunize healthy volunteers actively working with or in the vicinity of replicating Vaccinia virus with IMVAMUNE® (MVA-BN®)
    Medical condition: Healthy subjects actively working with or in the vicinity of replicating Vaccinia virus will receive immunization IMVAMUNE to offer protection against accidential Vaccinia virus infection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10041197 Smallpox PT
    12.1 10066048 Vaccinia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005825-75 Sponsor Protocol Number: 105909 MeMuRu-OKA 047 Start Date*: 2006-03-20
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and ...
    Medical condition: Active immunisation against mumps, measles, rubella and varicella
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046980 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002669-19 Sponsor Protocol Number: X04-VAR-402 Start Date*: 2004-12-23
    Sponsor Name:AVENTIS PASTEUR MSD S.P.A.
    Full Title: A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants.
    Medical condition: Active immunisation against varicella
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046980 PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002352-39 Sponsor Protocol Number: APHP220580 Start Date*: 2022-06-30
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Follow-up of Contact Persons at Risk of Monkeypox infection: prospective cohort study (MONKEY VAX)
    Medical condition: The research is proposed to people at risk of infection with the monkey pox virus (Monkey pox), and to whom an anti-pox vaccine is proposed according to the health authorities recommandations (JYNN...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006297-28 Sponsor Protocol Number: POX-MVA-023 Start Date*: 2008-07-30
    Sponsor Name:Bavarian Nordic A/S
    Full Title: An open-label Phase II study to evaluate immunogenicity and safety of a single IMVAMUNE® booster vaccination two years after the last IMVAMUNE® vaccination in former POX-MVA-005 vaccinees
    Medical condition: Healthy subjects - prevention of smallpox infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041197 Smallpox PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001608-37 Sponsor Protocol Number: 115555MMRV-063 Start Date*: 2011-12-16
    Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA
    Full Title: Open, randomised, controlled, multicenter Phase IIIb study to evaluate the immune response and safety, after the administration of GlaxoSmithKline Biologicals live attenuated measles mumps rubell...
    Medical condition: Vaccination of children from the age of 9 months up to 12 years inclusive against measles, mumps, rubella and varicella diseases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10028257 Mumps PT
    14.1 10021881 - Infections and infestations 10046980 Varicella PT
    14.1 10021881 - Infections and infestations 10039252 Rubella PT
    14.1 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003535-30 Sponsor Protocol Number: 200147 Start Date*: 2015-10-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the secon...
    Medical condition: Vaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10069613 Varicella immunisation PT
    19.0 10042613 - Surgical and medical procedures 10069628 Varicella immunization LLT
    19.0 100000004848 10063315 Varicella zoster virus DNA test positive LLT
    19.0 10021881 - Infections and infestations 10046983 Varicella zoster LLT
    19.0 10021881 - Infections and infestations 10046980 Varicella PT
    19.0 100000004858 10050331 Varicella-like rash LLT
    19.0 100000004848 10063144 Varicella zoster virus serology positive LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001332-22 Sponsor Protocol Number: RG_12-201 Start Date*: 2013-06-20
    Sponsor Name:University of Birmingham
    Full Title: PEPtalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer
    Medical condition: Exposure to Varicella by children who have cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10046980 Varicella PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-006065-14 Sponsor Protocol Number: 105908 Start Date*: 2006-04-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline's (GSK) Biologicals' measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and ...
    Medical condition: Healthy male and female children between 15 months and 6 years of age who previously received an MMR vaccine will receive one dose of MMR + V or MMRV. A second dose of varicella vaccine will be giv...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002676-41 Sponsor Protocol Number: 100388,103494,104105,104106 Start Date*: 2005-05-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on ...
    Medical condition: Healthy children between 12-22 months (including the day before the 23-month birthday) of age at the time of vaccination with no history of measles, mumps, rubella and varicella diseases/vaccination.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10028257 Mumps PT
    14.1 10021881 - Infections and infestations 10046980 Varicella PT
    14.1 10021881 - Infections and infestations 10039252 Rubella PT
    14.1 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) SK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005137-37 Sponsor Protocol Number: POX-MVA-035 Start Date*: 2013-07-15
    Sponsor Name:Bavarian Nordic A/S
    Full Title: Open-label, non-controlled, multicenter immunogenicity and safety study of MVA-BN® smallpox vaccine in children from birth to less than 12 years of age
    Medical condition: Prevention of smallpox infection in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10041197 Smallpox PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002861-19 Sponsor Protocol Number: MBL 0407 INT Start Date*: 2005-01-24
    Sponsor Name:LEO Pharma A/S
    Full Title: Long-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel. A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as di...
    Medical condition: Psoriasis of the scalp Extent: Minimum 10% of the total scalp area Disease severity: Graded as "moderate", "severe", or "very severe" according to the investigator's global assessment of disease se...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037115 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002864-27 Sponsor Protocol Number: MBL 0503 INT Start Date*: 2005-10-07
    Sponsor Name:LEO Pharma A/S
    Full Title: Calcipotriol plus Betamethasone Dipropionate Gel Compared to DAIVONEX/DOVONEX Scalp Solution in Patients with Scalp Psoriasis. A phase III study comparing a gel containing calcipotriol 50 mcg/g plu...
    Medical condition: Psoriasis of the scalp Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs Extent of scalp psoriasis involving 10% or more...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037115 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014339-19 Sponsor Protocol Number: ONO-4641POU006 Start Date*: 2010-03-26
    Sponsor Name:ONO Pharmaceutical Co., Ltd.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 20:42:55 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA